Current and future directions in mammalian target of rapamycin inhibitors development

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The mammalian target of the rapamycin (mTOR) signaling pathway regulates cell growth, survival, and angiogenesis.
• Dysregulation of the mTOR pathway is common in cancer, making it a key therapeutic target.
• Rapalogs like temsirolimus and everolimus are approved for specific cancers, with others in clinical trials.

Purpose of the Study:

• To review the literature on the mTOR pathway, its inhibitors, and their role in cancer treatment.
• To overview recent data on mTOR signaling and novel mTOR inhibitors.
• To discuss the development status of second-generation mTOR inhibitors.

Main Methods:

• Literature review of published data on the mTOR pathway and inhibitors.
• Analysis of preclinical and clinical data on mTOR inhibitors in various tumors.
• Overview of signaling pathways related to mTOR.

Main Results:

• Preclinical data suggest new mTOR inhibitors possess potent antiproliferative activity.
• These novel inhibitors demonstrate a favorable safety profile.
• In preclinical studies, mTOR inhibitors achieved disease stabilization or tumor regression and enhanced other anticancer treatments.

Conclusions:

• Published data on novel mTOR inhibitors are emerging but limited.
• Preclinical results indicate significant potential for new mTOR inhibitors in cancer therapy.
• Further research is warranted to fully elucidate the efficacy and safety of novel mTOR inhibitors in clinical settings.